Hassan Malek Z O, Awadalla Magid, Tan Timothy C, Scherrer-Crosbie Marielle, Bakar Rula Bany, Drobni Zsofia D, Zarif Azmaeen, Gilman Hannah K, Supraja Sama, Nikolaidou Sofia, Zhang Lili, Zlotoff Daniel A, Hickey Shea B, Patel Sagar A, Januzzi James L, Keane Florence, Passeri Jonathon J, Neilan Tomas G, MacDonald Shannon M, Jimenez Rachel B
Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardiology Department, Royal Papworth Hospital, Trumpington, Cambridge, United Kingdom.
Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardiology Department, Morriston Hospital, Swansea, Wales, United Kingdom.
Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):398-406. doi: 10.1016/j.ijrobp.2022.08.036. Epub 2022 Aug 24.
Conventional photon radiation therapy (RT) for breast cancer is associated with a reduction in global longitudinal strain (GLS) and an increase in troponin, N-terminal pro hormone B-type natriuretic peptide (NT-proBNP), and incident heart failure. The cardiac radiation exposure with proton-RT is much reduced and thus may be associated with less cardiotoxicity. The objective was to test the effect of proton-RT on GLS, troponin, and NT-proBNP.
We conducted a prospective, observational, single-center study of 70 women being treated with proton-RT for breast cancer. Serial measurements of GLS, high-sensitivity troponin I, and NT-proBNP were performed at prespecified intervals (before proton-RT, 4 weeks after completion of proton-RT, and again at 2 months after proton-RT).
The mean age of the patients was 46 ± 11 years, and the mean body mass index was 25.6 ± 5.2 kg/m; 32% of patients had hypertension, and the mean radiation doses to the heart and the left ventricle (LV) were 0.44 Gy and 0.12 Gy, respectively. There was no change in left ventricular ejection fraction (65 ± 5 vs 66 ± 5 vs 64 ± 4%; P = .15), global GLS (-21.7 ± 2.7 vs -22.7 ± 2.3 vs -22.8 ± 2.1%; P = .24), or segmental GLS from before to after proton-RT. Similarly, there was no change in either high-sensitivity troponin or NT-proBNP with proton-RT. However, in a post hoc subset analysis, women with hypertension had a greater decrease in GLS after proton-RT compared with women without hypertension (-21.3 ± 3.5 vs -24.0 ± 2.4%; P = .006).
Proton-RT did not affect LV function and was not associated with an increase in biomarkers. These data support the potential cardiac benefits of proton-RT compared with conventional RT.
乳腺癌的传统光子放射治疗(RT)与整体纵向应变(GLS)降低以及肌钙蛋白、N末端B型利钠肽原(NT-proBNP)升高和心力衰竭发生率增加有关。质子放疗的心脏辐射暴露显著降低,因此可能与较低的心脏毒性相关。本研究旨在测试质子放疗对GLS、肌钙蛋白和NT-proBNP的影响。
我们对70例接受质子放疗的乳腺癌女性患者进行了一项前瞻性、观察性、单中心研究。在预定时间间隔(质子放疗前、质子放疗结束后4周、质子放疗后2个月)对GLS、高敏肌钙蛋白I和NT-proBNP进行系列测量。
患者的平均年龄为46±11岁,平均体重指数为25.6±5.2kg/m²;32%的患者患有高血压,心脏和左心室(LV)的平均辐射剂量分别为0.44Gy和0.12Gy。左心室射血分数(65±5% vs 66±5% vs 64±4%;P = 0.15)、整体GLS(-21.7±2.7% vs -22.7±2.3% vs -22.8±2.1%;P = 0.24)或质子放疗前后的节段性GLS均无变化。同样,质子放疗后高敏肌钙蛋白或NT-proBNP也没有变化。然而,在事后亚组分析中,与无高血压的女性相比,有高血压的女性在质子放疗后GLS下降幅度更大(-21.3±3.5% vs -24.0±2.4%;P = 0.006)。
质子放疗不影响左心室功能,也与生物标志物升高无关。这些数据支持了与传统放疗相比,质子放疗对心脏具有潜在益处。